Abstract
The Stat6VT mouse model of atopic dermatitis (AD) is induced by T-cell-specific expression of a constitutively active form of the protein signal transducer and activator of transcription 6 (STAT6). Although AD-like lesions are known to develop in Stat6VT mice, this study was designed to determine if these mice develop acute and chronic phases of disease similar to humans. To address this, AD-like lesions from Stat6VT mice were harvested at two different timepoints relative to their onset. Lesions harvested within 1 week after development were defined as acute lesions, and those present for 1 month or more were defined as chronic lesions. Acute and chronic AD-like lesions from Stat6VT mice exhibited histologic findings and cytokine expression patterns similar to acute and chronic AD lesions in humans. Further analysis revealed increased levels of interleukin (IL)-33 transcripts in AD-like lesions compared to Stat6VT nonlesional and wild-type skin controls. Immunofluorescence also revealed increased numbers of IL-33+ keratinocytes in Stat6VT lesional skin and localized IL-33+ keratinocytes to a keratin 5+ subset. Furthermore, AD-like disease was more severe in IL-33-deficient Stat6VT mice compared to IL-33-sufficient Stat6VT mice. These studies suggest that Stat6VT mice can serve as a model of acute and chronic AD and that IL-33 may attenuate inflammation in this system.
Similar content being viewed by others
References
Ali S et al (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 104:18660–18665
Ali S et al (2011) The dual function cytokine IL-33 interacts with the transcription factor NF-kappaB to dampen NF-kappaB-stimulated gene transcription. J Immunol 187:1609–1616
Arpaia N et al (2015) A distinct function of regulatory T Cells in tissue protection. Cell 162:1078–1089
Beck LA et al (2014) Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371:130–139
Bieber T (2008) Atopic dermatitis. N Engl J Med 358:1483–1494
Brunner SM et al (2011) Interleukin-33 prolongs allograft survival during chronic cardiac rejection. Transpl Int 24:1027–1039
Bruns HA et al (2003) Expression of a constitutively active Stat6 in vivo alters lymphocyte homeostasis with distinct effects in T and B cells. J Immunol 170:3478–3487
Carriere V et al (2007) IL-33, the IL-1-like cytokine ligand for ST2 receptor, is a chromatin-associated nuclear factor in vivo. Proc Natl Acad Sci USA 104:282–287
Chackerian AA et al (2007) IL-1 receptor accessory protein and ST2 comprise the IL-33 receptor complex. J Immunol 179:2551–2555
Choi YS et al (2012) Nuclear IL-33 is a transcriptional regulator of NF-kappaB p65 and induces endothelial cell activation. Biochem Biophys Res Commun 421:305–311
Daniel C et al (2000) A gain-of-function mutation in STAT6. J Biol Chem 275:14255–14259
DaSilva SC et al (2012) Increased skin barrier disruption by sodium lauryl sulfate in mice expressing a constitutively active STAT6 in T cells. Arch Dermatol Res 304:65–71
Dillon SR et al (2004) Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol 5:752–760
Duan L et al (2012) Interleukin-33 ameliorates experimental colitis through promoting Th2/Foxp3(+) regulatory T-cell responses in mice. Mol Med 18:753–761
Ewald DA et al (2017) Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. J Allergy Clin Immunol 139:562–571
Gajardo T et al (2015) Exogenous interleukin-33 targets myeloid-derived suppressor cells and generates periphery-induced Foxp3(+) regulatory T cells in skin-transplanted mice. Immunology 146:81–88
Gandhi NA et al (2016) Targeting key proximal drivers of type 2 inflammation in disease. Nat Rev Drug Discov 15:35–50
Griesenauer B, Paczesny S (2017) The ST2/IL-33 axis in immune cells during inflammatory diseases. Front Immunol 8:475
Hanifin JM et al (2001) The eczema area and severity index (EASI): assessment of reliability in atopic dermatitis. EASI Evaluator Group. Exp Dermatol 10:11–18
Imai Y et al (2013) Skin-specific expression of IL-33 activates group 2 innate lymphoid cells and elicits atopic dermatitis-like inflammation in mice. Proc Natl Acad Sci USA 110:13921–13926
Jiang HR et al (2012) IL-33 attenuates EAE by suppressing IL-17 and IFN-gamma production and inducing alternatively activated macrophages. Eur J Immunol 42:1804–1814
Kakkar R et al (2012) Interleukin 33 as a mechanically responsive cytokine secreted by living cells. J Biol Chem 287:6941–6948
Kim BS et al (2013) TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation. Sci Transl Med 5:170ra116
Kouzaki H et al (2011) The danger signal, extracellular ATP, is a sensor for an airborne allergen and triggers IL-33 release and innate Th2-type responses. J Immunol 186:4375–4387
Li M et al (2006) Topical vitamin D3 and low-calcemic analogs induce thymic stromal lymphopoietin in mouse keratinocytes and trigger an atopic dermatitis. Proc Natl Acad Sci USA 103:11736–11741
Liew FY et al (2016) Interleukin-33 in health and disease. Nat Rev Immunol 16:676–689
Matsuda H et al (1997) Development of atopic dermatitis-like skin lesion with IgE hyperproduction in NC/Nga mice. Int Immunol 9:461–466
Matta BM et al (2014) IL-33 is an unconventional Alarmin that stimulates IL-2 secretion by dendritic cells to selectively expand IL-33R/ST2 + regulatory T cells. J Immunol 193:4010–4020
Matta BM et al (2016) Peri-alloHCT IL-33 administration expands recipient T-regulatory cells that protect mice against acute GVHD. Blood 128:427–439
Monticelli LA et al (2015) IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions. Proc Natl Acad Sci USA 112:10762–10767
Moussion C et al. (2008) The IL-1-like cytokine IL-33 is constitutively expressed in the nucleus of endothelial cells and epithelial cells in vivo: a novel ‘alarmin’?. PloS One. 3, e3331
Noel G et al (2016) Ablation of interaction between IL-33 and ST2 + regulatory T cells increases immune cell-mediated hepatitis and activated NK cell liver infiltration. Am J Physiol Gastrointest Liver Physiol 311:G313–G323
Oshio T et al (2017) Nuclear expression of IL-33 in epidermal keratinocytes promotes wound healing in mice. J Dermatol Sci 85:106–114
Oyoshi MK et al (2016) Thymic stromal lymphopoietin and IL-33 promote skin inflammation and vaccinia virus replication in a mouse model of atopic dermatitis. J Allergy Clin Immunol 138:283–286
Peine M et al (2016) IL-33 in T cell differentiation, function, and immune homeostasis. Trends Immunol 37:321–333
Popovic B et al. (2017) IL-33/ST2 pathway drives regulatory T cell dependent suppression of liver damage upon cytomegalovirus infection. PLoS Pathog. 13, e1006345
Rak GD et al (2016) IL-33-Dependent Group 2 innate lymphoid cells promote cutaneous wound healing. J Invest Dermatol 136:487–496
Ryu WI et al (2016) IL-33 down-regulates filaggrin expression by inducing STAT3 and ERK phosphorylation in human keratinocytes. J Dermatol Sci 82:131–134
Salimi M et al (2013) A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med 210:2939–2950
Savinko T et al (2013) ST2 regulates allergic airway inflammation and T-cell polarization in epicutaneously sensitized mice. J Investig Dermatol 133:2522–2529
Schiering C et al (2014) The alarmin IL-33 promotes regulatory T-cell function in the intestine. Nature 513:564–568
Schmitz J et al (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23:479–490
Sehra S et al (2008) IL-4 is a critical determinant in the generation of allergic inflammation initiated by a constitutively active Stat6. J Immunol 180:3551–3559
Sehra S et al (2010) IL-4 regulates skin homeostasis and the predisposition toward allergic skin inflammation. J Immunol 184:3186–3190
Sehra S et al (2016) Increased Th2 activity and diminished skin barrier function cooperate in allergic skin inflammation. Eur J Immunol 46:2609–2613
Seltmann J et al (2015) IL-33 impacts on the skin barrier by downregulating the expression of filaggrin. J Allergy Clin Immunol 135:1659–1661.e4
Serezani AP et al (2017) IL-4 impairs wound healing potential in the skin by repressing fibronectin expression. J Allergy Clin Immunol 139:142–151.e5
Soumelis V et al (2002) Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol 3:673–680
Souwer Y et al (2010) IL-17 and IL-22 in atopic allergic disease. Curr Opin Immunol 22:821–826
Turner MJ et al (2012) T helper cell subsets in the development of atopic dermatitis. J Drugs Dermatol 11:1174–1178
Turner MJ et al (2013) Topical application of a vitamin D analogue exacerbates atopic dermatitis and induces the atopic dermatitis-like phenotype in Stat6VT mice. Pediatr Dermatol 30:574–578
Turner MJ et al (2014) STAT6-mediated keratitis and blepharitis: a novel murine model of ocular atopic dermatitis. Investig Ophthalmol Vis Sci 55:3803–3808
Turnquist HR et al (2011) IL-33 expands suppressive CD11b + Gr-1(int) and regulatory T cells, including ST2L + Foxp3 + cells, and mediates regulatory T cell-dependent promotion of cardiac allograft survival. J Immunol 187:4598–4610
Vasanthakumar A et al (2015) The transcriptional regulators IRF4, BATF and IL-33 orchestrate development and maintenance of adipose tissue-resident regulatory T cells. Nat Immunol 16:276–285
Yin H et al (2013) IL-33 accelerates cutaneous wound healing involved in upregulation of alternatively activated macrophages. Mol Immunol 56:347–353
Yin H et al (2013) IL-33 promotes Staphylococcus aureus-infected wound healing in mice. Int Immunopharmacol 17:432–438
Yoo J et al (2005) Spontaneous atopic dermatitis in mice expressing an inducible thymic stromal lymphopoietin transgene specifically in the skin. J Exp Med 202:541–549
Zhao W, Hu Z (2010) The enigmatic processing and secretion of interleukin-33. Cell Mol Immunol 7:260–262
Acknowledgements
This work was supported by the Dermatology Foundation (Physician-Scientist CDA) to MJT, The Department of Veterans Affairs VA CDA2 (IK2 CX001019) to MJT and VA Merit (510BX000853) to JBT, the Ralph W. and Grace M. Showalter Research Trust to MJT and NIH grants to MHK (R01 AI095282), DFS (AG048946 and ES020866), and JBT (HL062996, AG048946, and ES020866). MRO and AK were supported by T32 AR062495.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Ethical approval
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
Rights and permissions
About this article
Cite this article
DaSilva-Arnold, S.C., Thyagarajan, A., Seymour, L.J. et al. Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis. Arch Dermatol Res 310, 197–207 (2018). https://doi.org/10.1007/s00403-018-1807-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00403-018-1807-y